Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AG-881 in Healthy Japanese and Non-Asian Subjects
NCT04145128Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorasidenib in glioma, astrocytoma and Oligodendroglioma (OG), sponsored by Agios Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Time of the Last Measurable Concentration, Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity and 5 more. Started Oct 2019; status: completed.
02
Drugs
vorasidenib
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT04145128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145128.